Multiple sclerosis (MS) is an immune-mediated inflammatory disease characterized by demyelination and degeneration in the ...

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.

Researchers at the Karolinska Institute in Sweden have identified 18 new potential drug targets for treating multiple ...

A study led by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central ...

A study led by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding ...

Imaging studies at the NIH Clinical Center showed that chronic active lesions with a paramagnetic rim exerted ongoing tissue ...

Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple ...

Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis ...